Orbus Therapeutics
Latest round
- Series A
Last raised
- Jul 2020
Total raised
- $41M
Investors
- 5
About Orbus Therapeutics
Orbus Therapeutics, Inc.Founded in 2012, Orbus Therapeutics, Inc. operates out of Palo Alto, US, specializing in therapies for rare diseases.G. BioHealth Partners, and Longitude Capital. The company's founders, Jason Levin and Victor Levin, have a history of expertise in the biotech sector, contributing to Orbus's strategic direction.Orbus Therapeutics specializes in the development and commercialization of innovative therapeutic products aimed at addressing the needs of patients suffering from rare diseases. The company's core focus is centered on eflornithine, a treatment targeted towards specific life-threatening conditions, including grade 3 astrocytoma. The drug works by inhibiting an enzyme necessary for cell growth, thereby slowing down or halting the progression of certain tumors. Currently, Orbus is primarily engaged in the North American and European markets, where it seeks to improve patient outcomes through its specialized treatment offerings.Orbus Therapeutics generates revenue through the commercialization of its therapeutic product, eflornithine, which is positioned within a specialized pharmaceutical segment. The company engages in direct-to-consumer sales as well as partnerships with healthcare providers and institutions that facilitate access to its treatments. Transactions are structured around the sale of eflornithine, with healthcare entities procuring the medication to administer to eligible patients. The pricing model is designed to reflect the unique value of treating rare conditions, ensuring that access to effective therapies is prioritized.In July 2020, Orbus Therapeutics, Inc. The company aims to explore opportunities in additional European markets and further penetrate the North American landscape by 2023, thereby broadening its outreach to patients in need of innovative treatments. Specific new products are in the pipeline, although exact release dates have not been outlined.
Who invested in Orbus Therapeutics
5 investors across 3 rounds
See all investors in Orbus Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Orbus Therapeutics
Who invested in Orbus Therapeutics?
Orbus Therapeutics has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Orbus Therapeutics raised?
Orbus Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Orbus Therapeutics last raise money?
Orbus Therapeutics's most recent round on record is a Series A, in Jul 2020.
What does Orbus Therapeutics do?
Orbus Therapeutics is a biotechnology company.
Where is Orbus Therapeutics headquartered?
Orbus Therapeutics is headquartered in Palo Alto, US.
Which VCs invest in companies like Orbus Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Orbus Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Orbus Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.